Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Status:
Terminated
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing
the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic
sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites
in North America, Europe, Australia, and Asia. The planned duration of treatment with study
drug is 52 weeks.